Can This Coronavirus Stock Soar 230%? 5-Star Analyst Thinks So

Diversification is a tried-and-true strategy when investing in stocks. Drug maker Sorrento Therapeutics (SRNE) is applying the same thought process in its battle against the coronavirus. The multi-pronged approach involving a search for antiviral therapies, a vaccine and the production of testing kits, has paid off handsomely in the market, with the stock appreciating by 115% year-to-date.Last week, Sorrento revealed more positive details from its COVID-19 vaccine program’s progress. In a pre-clinical trial, the company’s candidate, T-VIVA-19, was able to generate neutralizing antibodies in 80% of mice injected with the vaccine, and thus completely prevent cells from being infected with …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.